Pharmacogenomics
Statin Therapy, Genetics and Heart Disease - March 4, 2015
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
Jessica Mega et al., Lancet, March 2015
Jessica Mega et al., Lancet, March 2015
Statins work for those at highest risk of heart attack - study, the Guardian, Mar 3
the Guardian, Mar 3Dosing guideline for simvastatin and SLCO1B1, Clinical Pharmacogenomics Implementation Consortium 2014 update
Clinical Pharmacogenomics Implementation Consortium 2014 updatePharmacogenetics and statin treatment: Reality or theory?
Bousoula E et al. Curr Vasc Pharmacol 2015 Jan 30.
Bousoula E et al. Curr Vasc Pharmacol 2015 Jan 30.
Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation.
Kim Kyungpil et al. Genome Biol. 2014 (9) 460
Kim Kyungpil et al. Genome Biol. 2014 (9) 460
No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction.
Leusink Maarten et al. Pharmacogenomics 2014 Aug (11) 1471-7
Leusink Maarten et al. Pharmacogenomics 2014 Aug (11) 1471-7
Pharmacogenetics of statin-induced myopathy: A focused review of the clinical translation of pharmacokinetic genetic variants.
Talameh Jasmine A et al. J Pharmacogenomics Pharmacoproteomics 2014 Apr 23. (2)
Talameh Jasmine A et al. J Pharmacogenomics Pharmacoproteomics 2014 Apr 23. (2)
The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
Ramsey L B et al. Clin. Pharmacol. Ther. 2014 Oct (4) 423-8
Ramsey L B et al. Clin. Pharmacol. Ther. 2014 Oct (4) 423-8
Pharmacogenomics, lipid disorders, and treatment options.
Gryn S E et al. Clin. Pharmacol. Ther. 2014 Jul (1) 36-47
Gryn S E et al. Clin. Pharmacol. Ther. 2014 Jul (1) 36-47
Cardiovascular pharmacogenomics: expectations and practical benefits.
Turner R M et al. Clin. Pharmacol. Ther. 2014 Mar (3) 281-93
Turner R M et al. Clin. Pharmacol. Ther. 2014 Mar (3) 281-93
Genetics and personalized medicine--a role in statin therapy?
Patel Jaideep et al. Curr Atheroscler Rep 2014 Jan (1) 384
Patel Jaideep et al. Curr Atheroscler Rep 2014 Jan (1) 384
Statin myotoxicity: a review of genetic susceptibility factors.
Needham M et al. Neuromuscul. Disord. 2014 Jan (1) 4-15
Needham M et al. Neuromuscul. Disord. 2014 Jan (1) 4-15
Antidepressants, Pharmacogenomics and Public Health - February 23, 2015
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
Hicks J K et al. Clin. Pharmacol. Ther. 2013 May (5) 402-8
Hicks J K et al. Clin. Pharmacol. Ther. 2013 May (5) 402-8
CPIC dosing guideline for amitriptyline and CYP2C19, CYP2D6
The CPIC Dosing Guideline for amitriptyline recommends an alternative drug for CYP2D6 or CYP2C19 ultrarapid metabolizers and for CYP2D6 poor metabolizers. Consider a 50% dose reduction for CYP2C19 poor metabolizers and a 25% dose reduction for CYP2D6 intermediate metabolizers, 2013
The CPIC Dosing Guideline for amitriptyline recommends an alternative drug for CYP2D6 or CYP2C19 ultrarapid metabolizers and for CYP2D6 poor metabolizers. Consider a 50% dose reduction for CYP2C19 poor metabolizers and a 25% dose reduction for CYP2D6 intermediate metabolizers, 2013
Pharmacogenomic testing for dose adjustment of selected antidepressants
CDC Tier-2 classification (under psychiatry)
CDC Tier-2 classification (under psychiatry)
Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
Altar C A et al. Pharmacogenomics J. 2015 Feb 17.
Altar C A et al. Pharmacogenomics J. 2015 Feb 17.
Identifying genetic loci associated with antidepressant drug response with drug-gene interaction models in a population-based study.
Noordam Raymond et al. J Psychiatr Res 2015 Jan 20.
Noordam Raymond et al. J Psychiatr Res 2015 Jan 20.
Genetic determinants of selective serotonin reuptake inhibitor related sexual dysfunction.
Stevenson James M et al. Pharmacogenomics 2014 Nov (14) 1791-1806
Stevenson James M et al. Pharmacogenomics 2014 Nov (14) 1791-1806
Genetic prediction of antidepressant drug response and nonresponse in Korean patients.
Lim Shinn-Won et al. PLoS ONE 2014 (9) e107098
Lim Shinn-Won et al. PLoS ONE 2014 (9) e107098
Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans.
Wong Ma-Li et al. Am J Psychiatry 2014 Sep 15.
Wong Ma-Li et al. Am J Psychiatry 2014 Sep 15.
Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians.
Zai Gwyneth et al. Pharmacogenomics 2014 Jun (8) 1147-57
Zai Gwyneth et al. Pharmacogenomics 2014 Jun (8) 1147-57
Understanding the pharmacogenetics of selective serotonin reuptake inhibitors.
Fabbri Chiara et al. Expert Opin Drug Metab Toxicol 2014 Aug (8) 1093-118
Fabbri Chiara et al. Expert Opin Drug Metab Toxicol 2014 Aug (8) 1093-118
From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.
Fabbri Chiara et al. Can J Psychiatry 2014 Feb (2) 62-75
Fabbri Chiara et al. Can J Psychiatry 2014 Feb (2) 62-75
Is there a role for antidepressant and antipsychotic pharmacogenetics in clinical practice in 2014?
Mulsant Benoit H et al. Can J Psychiatry 2014 Feb (2) 59-61
Mulsant Benoit H et al. Can J Psychiatry 2014 Feb (2) 59-61
Check out genes and genomewide association studies reported in relation to antidepressant use and outcomes, from the HUGE Navigator
from the HUGE NavigatorCheck out genetic tests related to selective serotonin reuptake inhibitor toxicity, from the NIH Genetic Testing Registry
from the NIH Genetic Testing RegistryClopidogrel, Pharmacogenomics and Drug Therapy: Where Are We? - February 9, 2015
CYP2C19/clopidogrel | non-ST-segment elevation acute coronary syndrome, ST-elevation myocardial infarction, myocardial infarction, stroke, peripheral arterial disease | PGx |
A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users.
Ruben L. Osnabrugge et al. Genetics in Medicine, June 19, 2014
Ruben L. Osnabrugge et al. Genetics in Medicine, June 19, 2014
Pilot study: incorporation of pharmacogenetic testing in medication therapy management services.
Haga SB, et al. Pharmacogenomics. 2014 Nov;15(14):1729-1737.
Haga SB, et al. Pharmacogenomics. 2014 Nov;15(14):1729-1737.
CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.
Sorich MJ, et al. Circ Cardiovasc Genet. 2014 Dec;7(6):895-902.
Sorich MJ, et al. Circ Cardiovasc Genet. 2014 Dec;7(6):895-902.
Clopidogrel: A multifaceted affair.
Martínez-Quintana E, J Clin Pharmacol. 2015 Jan;55(1):1-9
Martínez-Quintana E, J Clin Pharmacol. 2015 Jan;55(1):1-9
Pharmacogenomic Testing in Practice: How Much Evidence Do We Need? - November 26, 2014
Evidence required to demonstrate clinical utility of pharmacogenetic testing: The debate continues.
N K Gillis and F Innocenti. Clinical Pharmacology & Therapeutics (2014); 96 6, 655–657.
N K Gillis and F Innocenti. Clinical Pharmacology & Therapeutics (2014); 96 6, 655–657.
Useless until proven effective: The clinical utility of preemptive pharmacogenetic testing.
A C J W Janssens and P A Deverka Clinical Pharmacology & Therapeutics (2014); 96 6, 652–654.
A C J W Janssens and P A Deverka Clinical Pharmacology & Therapeutics (2014); 96 6, 652–654.
Meaningful use of pharmacogenetics.
M J Ratain and J A Johnson Clinical Pharmacology & Therapeutics (2014); 96 6, 650–652.
M J Ratain and J A Johnson Clinical Pharmacology & Therapeutics (2014); 96 6, 650–652.
Evidence-based Pharmacogenomic Testing: Where are we? - October 16, 2014
Editorial: A call for accurate pharmacogenetic labeling: Telling it like it is.
Wylie Burke, et al. JAMA Internal Medicine, October 13, 2014
Wylie Burke, et al. JAMA Internal Medicine, October 13, 2014
Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels.
Bo Wang, et al. JAMA Internal Medicine, October 13, 2014
Bo Wang, et al. JAMA Internal Medicine, October 13, 2014
CDC paper: Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.
Dotson W et al, Clin Pharmacol Ther. 2014 Apr;95(4):394-402.
.Dotson W et al, Clin Pharmacol Ther. 2014 Apr;95(4):394-402.
Pharmacogenomics: Gap Between Research and Practice - September 4, 2014
New study reveals pharmacogenomic knowledge gaps among physicians, PharmGKB blog post, Aug 29
PharmGKB blog post, Aug 29Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties.
Dickinson Barry, et al. Pharmacogenomics and personalized medicine, July 2014
Dickinson Barry, et al. Pharmacogenomics and personalized medicine, July 2014
Implementation of personalized medicine services in community pharmacies: need for more education. Alexander KM, et al. J Am Pharm Assoc (2003). 2014 Aug 22:e326-e333.
Alexander KM, et al. J Am Pharm Assoc (2003). 2014 Aug 22:e326-e333.CDC paper: Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Dotson W et al, Clin Pharmacol Ther. 2014 Apr;95(4):394-402.
. Dotson W et al, Clin Pharmacol Ther. 2014 Apr;95(4):394-402.
.png)
No hay comentarios:
Publicar un comentario